>> basically stated what the PR <<
Sorry, can't even think of trying to read a PR today. Moving slow and foggy.
>> greater survival advantage than any other P3 heretofore published late stage prostate cancer trial. <<
thanks.
My thesis and postdoctoral work was MHC..... cell-mediated responses across a major barrier, serology, transfection of MHC variants to restrict anti-viral responses, etc. I know what T cells can do. They are tough. They can beat the stuffing out of cancers, across relatively minor transplantion barriers. I was off to study exactly that (rejection of MHC-induced fibrosarcomas across non-MHC transplantation barriers), at Jackson Labs, for my first postdoc..... with the world's expert on "minor" transplantation antigens. But then I heard about a lab moving from Dallas to a place where they had good beer, so I decided to change projects.
I've also studied the immunogenicity of spontaneous and chemically-induced cancers in exacting animal models (cancers of recent origin, experiments conducted with early-passage cells in the exact substrain of origin, etc.).
I therefore know what I want survival curves to look like. I don't believe that a majority of patients can be significantly helped (not discounting some value from "adjuvant" effects) with cancer vaccines, but I expect a decent frequency of cures where and if there's a small percentage of individuals whose cancers can be "marked" by the immune system.
I would love to hear of a few long-term survivors among g>7.
Can't wait to see the data in tables/figures, as I've been picturing them for about 20 years.
:-)
aside.... "adjuvant", not in context of immunology. |
